Navigation Links
Actinium Pharmaceuticals to Host Corporate Update and Virtual Roadshow Conference Call on November 11
Date:10/31/2013

NEW YORK, Oct. 31, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing  innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will host a general corporate update and Virtual Roadshow to discuss the current plans for Iomab™-B at 11:00 AM EDT on November 11, 2013.

The company will discuss the outcome of the recent end of phase two FDA meeting and also the next steps for its Iomab™-B product candidate which is being readied for a pivotal trial.  Iomab™-B has completed several physician sponsored clinical trials examining its potential as a bone marrow conditioning regimen for hematopoietic stem cell transplantation (HSCT) in various blood cancers including a phase I/II study (study 1432) in relapsed and/or refractory elderly acute myeloid leukemia (AML) patients.  The results of study 1432 demonstrated the potential of Iomab™-B to create a new treatment paradigm for HSCT by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HCST; reducing post-transplant complications; and showing a clear survival benefit including curative potential.  

Webcast / Telecast Information:

Date: Tuesday, November 11, 2013

Time: 11:00 AM EDT

US Dial-in (Toll-free): 1-877-705-6003

International Dial-in: 1-201-493-6725

For the live and archived webcast, please visit the Investors page on the Actinium website at www.actiniumpharmaceuticals.com or https://viavid.webcasts.com/starthere.jsp?ei=1025173

A replay of the call will be available through December 11, 2013. To access the replay, please call 1-877-870-5176 if calling from '/>"/>

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
3. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
4. Actinium Pharmaceuticals Strengthens Management Team
5. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
6. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
7. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
8. Actinium Pharmaceuticals Announces New Round of Financing
9. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
10. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
11. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , September 1, 2015 ... on the basis of sectors, products & services ... globally coupled with the increasing demand of advanced ... expected to propel the growth for bioinformatics market. ... information efficiently is known as bioinformatics. Decreasing cost ...
(Date:9/1/2015)... , Aug. 31, 2015 Research and ... the "Regulatory Affairs for Support Staff (London, UK ... This two day course provides an ... drug development and has been designed specifically for those ... You will gain an overview of EU regulatory procedures ...
(Date:9/1/2015)... LONDON , September 1, 2015 - ... of GARFIELD-AF R egistry data presented ... real-world insights on the evolution of ... -   The first-ever two-year ... showcased at ESC Congress 2015 expose that all-cause death was the most frequent ...
Breaking Medicine Technology:Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4Regulatory Affairs for Support Staff Seminar (London, UK - September 24-25, 2015) 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 2Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 3Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 4Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 5Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 6Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 7Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 8Global Atrial Fibrillation Registry Presents Two-Year Outcomes Data In More Than 17,000 Newly Diagnosed AF Patients 9
(Date:9/1/2015)... ... September 01, 2015 , ... ... managed, stress created from everyday life changes can lead to very serious, life-altering ... support for coping with stress. Herbal supplement manufacturer MediHerb has coupled ...
(Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary Hospital hosted the ... 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community College in Brooklyn in ... of whom work for Calvary, and two junior counselors who were campers themselves just ...
(Date:9/1/2015)... ... , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) has once ... Style 50 Report that recognizes companies that provide the best career opportunities for Hispanic ... from number 24 to 21 of the 50 Best Companies for Latinas. The LATINA ...
(Date:9/1/2015)... , ... September 01, 2015 ... ... better therapeutic options to efficiently cure and prevent different malignancies. Some options ... have different pathophysiological properties due to which distinctive approach is necessary for ...
(Date:9/1/2015)... ... September 01, 2015 , ... As part of its ... Shield of Minnesota (Blue Cross) has announced Doctor On Demand as the company’s ... Doctor On Demand provides immediate access to Board Certified physicians or next-day appointments ...
Breaking Medicine News(10 mins):Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3
... cardiac cells may make them more resilient during real attack, ... Doctors have long known that the creation of a ... blood flow to arteries -- can actually reduce the damage ... know how that protective effect occurs, according to research from ...
... groups concerned about growing rates of obesity, diabetes, heart ... other illness linked to chemical exposure, said today that ... administrator with expertise and information for solutions to the ... , With so many different chemicals ...
... Dec. 12 [The Washington Post Friday ... Drug Administration and the White House are considering easing the ... fish. Scientists at the Environmental Protection Agency reportedly are ... move is one of several "midnight" rules and policy changes ...
... have better prognosis, study finds , , FRIDAY, Dec. 12 (HealthDay ... increase the risk of getting breast cancer, but women who ... lower risk of dying from the disease, a new study ... a particular type of cancer that is easier to treat," ...
... THE U.S. COMMITMENT TO GLOBAL HEALTH: RECOMMENDATIONS FOR THE ... is an important investment for the United States, even ... report describes areas that require the most attention, emphasizes ... and makes specific recommendations regarding funding and coordination of ...
... disease stabilize or improve, study shows , , FRIDAY, ... of medicines designed to boost immune function can ... results from an ongoing Mayo Clinic study. , ... drug called pomalidomide with dexamethasone (pom/dex) improved or ...
Cached Medicine News:Health News:Research Explains Benefit of 'Mini Heart Attack' 2Health News:Scientists, Physicians, Health, and Environmental Justice Advocates to New Obama EPA Director: 'We Look Forward to Toxic Chemical Regulatory Reform' 2Health News:HRT Users Who Get Breast Cancer Less Likely to Die 2Health News:HRT Users Who Get Breast Cancer Less Likely to Die 3Health News:Combo Therapy Helps Multiple Myeloma Patients 2
... the newest and most advanced automated immunoassay ... AIA-1800 launches with a full menu of ... reproductive, cardiac, and anemia assays. ,The AIA-1800 ... primary tube sampling, auto dilution, auto pretreatment, ...
EZ-PSA is a one-step immunoassay for the rapid, qualitative determination of human Prostate Specific Antigen (PSA) in whole blood. The test is intended for professional use as an aid in the diagnosis...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
... Functional Vision, Quality of Vision and ... both target illumination and glare luminance ... results. Day/Night testing with/without glare and ... and all ANSI standards. All Light ...
Medicine Products: